Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Vertebrate host defense against infection is mediated by the combined functions of the innate and adaptive arms of the immune system. Vaccination typically targets the adaptive immune response  promoting long-lived antibody and T cell responses specific to the pathogen in question. However, an alternative strategy would be to boost the non-specific effector functions of the innate immune system thereby promoting host resistance against multiple infectious agents. BCG (Bacille Calmette Guerin) is a century old vaccine that utilizes an attenuated strain of Mycobacterium bovis to prevent  tuberculosis (TB). While now recognized to provide inconsistent protection against adult pulmonary TB, BCG is still employed to protect infants and children against disseminated, extra-pulmonary forms of the disease. Interestingly, BCG vaccination has been known for over 60 years to have non-specific beneficial effects reducing all-cause mortality in infants as well as promoting tumor regression and is a widely used therapy for bladder cancer. The basis of these off- target effects of BCG is poorly understood but lately has received a lot of investigation as a possible manifestation of a phenomenon called “trained immunity”.  

Exciting  new research in the TB field has indicated that when administered to non-human primates intravenously (iv) instead of by the conventional intradermal/subcutaneous (sc) route, BCG can induce sterilizing immunity against aerosol Mycobacterium tuberculosis challenge. Our group has studied the possible contribution of innate immune mechanisms to this unusual protection and in the process discovered that when given iv (but not sc ) BCG also induces striking resistance against intranasally administered SARS-CoV-2 in mouse models. My talk will focus on the immunological mechanisms underlying this non-specific protection and more generally on how innate immune stimulation could be used to promote host resistance against respiratory pathogens. 

 

University members only.

Forthcoming events

The Neonatology Canon Project: Examining the Research Endeavor Through Comprehensive Aggregation of Randomized Aggregation of Randomized Trials

Tuesday, 21 May 2024, 1pm to 2pm @ Richard Doll Lecture Theatre, Richard Doll Building, Old Road Campus, Headington, OX3 7LF

Opium as a carcinogen: new insights from the Golestan Cohort Study

Tuesday, 28 May 2024, 1pm to 2pm @ Richard Doll Lecture Theatre, Richard Doll Building, Old Road Campus, Headington, OX3 7LF

Exploiting electronic health records to improve infection management

Monday, 03 June 2024, 1pm to 2pm @ BDI/OxPop Building LG seminar rooms

Title TBC

Tuesday, 04 June 2024, 1pm to 2pm @ Richard Doll Lecture Theatre, Richard Doll Building, Old Road Campus, Headington, OX3 7LF

Prevention of Chronic Kidney Disease Progression

Tuesday, 11 June 2024, 1pm to 2pm @ Richard Doll Lecture Theatre, Richard Doll Building, Old Road Campus, Headington, OX3 7LF